Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer (Q37755092)

22 August 2017

title

Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer (English)

1 reference

22 August 2017

M Spears

1

1 reference

22 August 2017

J Kenicer

series ordinal

2

1 reference

22 August 2017

A F Munro

series ordinal

3

1 reference

22 August 2017

J M S Bartlett

series ordinal

4

1 reference

22 August 2017

publication date

1 August 2008

1 reference

22 August 2017

published in

Biomarkers in Medicine

1 reference

22 August 2017

volume

2

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

397-407

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Molecular approach to breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

The ErbB receptor tyrosine family as signal integrators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Hormonal therapy for postmenopausal breast cancer: the science of sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Targeted therapy in breast cancer: the HER-2/neu gene and protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Estrogen-receptor biology: continuing progress and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Proximal events in signaling by plasma membrane estrogen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

HER-2 and topoisomerase II as predictors of response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.4.397

21 January 2018

Identifiers

DOI

10.2217/17520363.2.4.397

1 reference

22 August 2017

1 reference